The elevated circulating CD8+PD-1+/CD4+PD-1+ ratio prior to immunotherapy has also been shown to be correlated with good survival times in advanced non-small cell lung cancer patients treated with anti-PD-(L)1treatment [37]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.